Teva, Cephalon Sue FDA Over Generic Provigil Exclusivity
By Megan Stride ( April 4, 2012, 5:25 PM EDT) -- Teva Pharmaceuticals USA Inc. and Cephalon Inc. sued the U.S. Food and Drug Administration in Washington federal court Tuesday seeking to bar the agency from robbing Teva of the marketing exclusivity period they say it earned through patent certifications for its generic version of Cephalon's blockbuster sleep disorder drug Provigil....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.